A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Purpose
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed. XEN63 is an investigational device for the treatment of intraocular pressure (IOP) in patients with glaucoma when both medical and conventional surgical treatments have failed (for US approval) and when medical treatments have failed (for outside US [OUS] approval). Participants will be placed in one of two groups called study arms. One group will receive the XEN63 gel stent ab interno (inside the eye) and the other group will receive the XEN63 gel stent ab externo (outside the eye). Approximately 130 participants aged 45 years or older with glaucoma will be enrolled in this study at approximately 32 sites in the United States. Participants will receive XEN63 implanted using either the ab interno approach or the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
Condition
- Primary Open Angle Glaucoma
Eligibility
- Eligible Ages
- Over 45 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of glaucoma in the study eye (SE) (meeting criterion a or b) 1. That meets the following refractory glaucoma criteria of eyes diagnosed with glaucoma uncontrolled by maximal medical therapy (four or more classes of intraocular pressure (IOP)-lowering medications, or fewer in cases where it has been documented that certain medication classes cannot be tolerated or are contraindicated), and failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery, tube shunt) 2. Uncontrolled by medical therapy (to meet out-of-US [OUS] requirements) with participants who only have glaucoma uncontrolled by medical therapy (non-refractory glaucoma), a maximum of 10 participants who meet only criterion b (and not a) will be enrolled in each cohort.
Exclusion Criteria
- History of angle-closure glaucoma where the angle has not been surgically opened in the SE. - History of secondary open-angle glaucoma (e.g., neovascular, pigmentary, pseudoexfoliative, uveitic, angle recession/traumatic glaucoma, etc.) in the SE. - Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) in the SE.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental XEN63 Ab Externo |
Participants will be implanted with XEN63 via ab externo surgical approach in the study eye. Participants will be followed for up to 12 months. |
|
|
Experimental XEN63 Ab Interno |
Participants will be implanted with XEN63 via ab interno surgical approach in the study eye. Participants will be followed for up to 12 months. |
|
Recruiting Locations
Glendale 5295985, Arizona 5551752 85306
Culver City 5341114, California 5332921 90232
Petaluma 5382232, California 5332921 94954
Aurora 5412347, Colorado 5417618 80045
Colorado Springs 5417598, Colorado 5417618 80924
Brandon 4148757, Florida 4155751 33511
Vero Beach 4176409, Florida 4155751 32960
Roswell 4219934, Georgia 4197000 30076
Peoria 4905687, Illinois 4896861 61615
Overland Park 4276873, Kansas 4273857 66213
Minneapolis 5037649, Minnesota 5037779 55431
Omaha 5074472, Nebraska 5073708 68137
Oklahoma City 4544349, Oklahoma 4544379 73112
Bala-Cynwyd 5178892, Pennsylvania 6254927 19004
Philadelphia 4560349, Pennsylvania 6254927 19107
Dallas 4684888, Texas 4736286 75231
Dallas 4684888, Texas 4736286 75390
Site Coordinator
214-645-2014
El Paso 5520993, Texas 4736286 79902
Roanoke 4782167, Virginia 6254928 24016
More Details
- Status
- Recruiting
- Sponsor
- AbbVie